MVC
高端疫苗生物製劑股份有限公司
MVC is a Taiwan TPEx-listed biotechnology company; its most advanced asset is ENVACGEN (Vietnam marketing authorization approved, Prevention of enterovirus 71 infection), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ENVACGEN | — | Vietnam marketing authorization approved | Prevention of enterovirus 71 infection | Vietnam | 2026-03-17 | Company disclosure |
| Fluvacgen | — | Marketing authorization obtained | Prevention of seasonal influenza | Taiwan | 2025-04-30 | Company disclosure |
| Quadrivalent influenza vaccine | — | Authorized; public-funded market supplied | Prevention of seasonal influenza | Taiwan | 2025-04-30 | Company disclosure |
Key events
- Business update (company filing)
- Business update (company filing)
- Business update (company filing)